U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Plasmablastic Lymphoma

MedGen UID:
1675391
•Concept ID:
C4763788
•
Neoplastic Process

Definition

Plasmablastic lymphoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Plasmablastic Lymphoma

Professional guidelines

PubMed

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.
Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members
Ann Oncol 2018 Aug 1;29(8):1687-1700. doi: 10.1093/annonc/mdy167. PMID: 29924296

Recent clinical studies

Etiology

Hematologic cancers in individuals infected by HIV.
Carbone A, Vaccher E, Gloghini A
Blood 2022 Feb 17;139(7):995-1012. doi: 10.1182/blood.2020005469. PMID: 34469512
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, Ambinder R, Cheever M, Gulley JL, Goncalves PH, Wang HW, Uldrick TS, Yarchoan R
J Immunother Cancer 2021 Feb;9(2) doi: 10.1136/jitc-2020-002097. PMID: 33608378Free PMC Article
Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K
Ann Hematol 2020 Sep;99(9):2141-2148. Epub 2020 May 26 doi: 10.1007/s00277-019-03853-1. PMID: 32451711
Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L
Oncol Rep 2015 Apr;33(4):1615-20. Epub 2015 Feb 17 doi: 10.3892/or.2015.3808. PMID: 25695332Free PMC Article
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU
Transplantation 2012 Mar 15;93(5):543-50. doi: 10.1097/TP.0b013e318242162d. PMID: 22234349

Diagnosis

Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K
Ann Hematol 2020 Sep;99(9):2141-2148. Epub 2020 May 26 doi: 10.1007/s00277-019-03853-1. PMID: 32451711
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, Sawayama Y, Hata T, Ohshima K, Miyazaki Y
Oncol Res Treat 2020;43(3):112-116. Epub 2019 Dec 16 doi: 10.1159/000504608. PMID: 31842017
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D, Kalisch A, Wilhelm M, Birkmann J
Ann Hematol 2017 Jun;96(6):967-970. Epub 2016 Dec 23 doi: 10.1007/s00277-016-2904-7. PMID: 28011983
Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L
Oncol Rep 2015 Apr;33(4):1615-20. Epub 2015 Feb 17 doi: 10.3892/or.2015.3808. PMID: 25695332Free PMC Article
HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
Castillo J, Pantanowitz L, Dezube BJ
Am J Hematol 2008 Oct;83(10):804-9. doi: 10.1002/ajh.21250. PMID: 18756521

Therapy

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S, Pauly M, Blum WG, Qayed M, Dhodapkar MV, Elkhalifa M, Watkins B, Schoettler M, Horwitz E, Parikh S, Chandrakasan S, Leung K, Bryson E, Deeb L, Kaufman JL, Worthington-White D, Alazraki A, Schecter JM, Madduri D, Jackson CC, Zudaire E, Taraseviciute-Morris A, Babich A, Nesheiwat T, Vogel M, Lendvai N, Pacaud L, Williams KM
J Immunother Cancer 2023 May;11(5) doi: 10.1136/jitc-2023-006684. PMID: 37137553Free PMC Article
Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.
Hertel N, Merz H, Bernd HW, Bernard V, Künstner A, Busch H, von Bubnoff N, Feller AC, Witte HM, Gebauer N
J Cancer Res Clin Oncol 2021 Oct;147(10):3043-3050. Epub 2021 Mar 3 doi: 10.1007/s00432-021-03580-z. PMID: 33660007Free PMC Article
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, Sawayama Y, Hata T, Ohshima K, Miyazaki Y
Oncol Res Treat 2020;43(3):112-116. Epub 2019 Dec 16 doi: 10.1159/000504608. PMID: 31842017
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D, Kalisch A, Wilhelm M, Birkmann J
Ann Hematol 2017 Jun;96(6):967-970. Epub 2016 Dec 23 doi: 10.1007/s00277-016-2904-7. PMID: 28011983
HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
Castillo J, Pantanowitz L, Dezube BJ
Am J Hematol 2008 Oct;83(10):804-9. doi: 10.1002/ajh.21250. PMID: 18756521

Prognosis

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S, Pauly M, Blum WG, Qayed M, Dhodapkar MV, Elkhalifa M, Watkins B, Schoettler M, Horwitz E, Parikh S, Chandrakasan S, Leung K, Bryson E, Deeb L, Kaufman JL, Worthington-White D, Alazraki A, Schecter JM, Madduri D, Jackson CC, Zudaire E, Taraseviciute-Morris A, Babich A, Nesheiwat T, Vogel M, Lendvai N, Pacaud L, Williams KM
J Immunother Cancer 2023 May;11(5) doi: 10.1136/jitc-2023-006684. PMID: 37137553Free PMC Article
Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.
Hertel N, Merz H, Bernd HW, Bernard V, Künstner A, Busch H, von Bubnoff N, Feller AC, Witte HM, Gebauer N
J Cancer Res Clin Oncol 2021 Oct;147(10):3043-3050. Epub 2021 Mar 3 doi: 10.1007/s00432-021-03580-z. PMID: 33660007Free PMC Article
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, Sawayama Y, Hata T, Ohshima K, Miyazaki Y
Oncol Res Treat 2020;43(3):112-116. Epub 2019 Dec 16 doi: 10.1159/000504608. PMID: 31842017
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D, Kalisch A, Wilhelm M, Birkmann J
Ann Hematol 2017 Jun;96(6):967-970. Epub 2016 Dec 23 doi: 10.1007/s00277-016-2904-7. PMID: 28011983
Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L
Oncol Rep 2015 Apr;33(4):1615-20. Epub 2015 Feb 17 doi: 10.3892/or.2015.3808. PMID: 25695332Free PMC Article

Clinical prediction guides

Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.
Hertel N, Merz H, Bernd HW, Bernard V, Künstner A, Busch H, von Bubnoff N, Feller AC, Witte HM, Gebauer N
J Cancer Res Clin Oncol 2021 Oct;147(10):3043-3050. Epub 2021 Mar 3 doi: 10.1007/s00432-021-03580-z. PMID: 33660007Free PMC Article
Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K
Ann Hematol 2020 Sep;99(9):2141-2148. Epub 2020 May 26 doi: 10.1007/s00277-019-03853-1. PMID: 32451711
Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.
Oka S, Ono K, Nohgawa M
Leuk Lymphoma 2019 Sep;60(9):2152-2157. Epub 2019 Mar 19 doi: 10.1080/10428194.2019.1574003. PMID: 30887866
Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L
Oncol Rep 2015 Apr;33(4):1615-20. Epub 2015 Feb 17 doi: 10.3892/or.2015.3808. PMID: 25695332Free PMC Article
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU
Transplantation 2012 Mar 15;93(5):543-50. doi: 10.1097/TP.0b013e318242162d. PMID: 22234349

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...